Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT05974410 Available - Breast Cancer Clinical Trials

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Start date: n/a
Phase:
Study type: Expanded Access

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT04681248 Available - Ovarian Cancer Clinical Trials

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.

NCT ID: NCT04566393 Available - Colorectal Cancer Clinical Trials

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

NCT ID: NCT02209441 Available - Gastric Cancer. Clinical Trials

Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

- To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin/5-fluorouracil) as first-line treatment for advanced gastric cancer - The design of the study incorporated a standard 3 + 3 dose escalation procedure to guide elevation of the sorafenib dosage to the next level